

Title of Meeting:	Governing Body Meeting			Agenda Item: 9.3		
Date of Meeting:	25 February 2021			Session (Tick)		
Paper Title:	Quality and Clinical Governance Committee Key Messages			Public	X	
				Private		
				Workshop		
Responsible Governing Body Member Lead Kate Kennady, Lay Member for PPE and Chair of the Quality & Clinical Governance Committee			Report Author and Job Title Kate Kennady, Lay Member for PPE and Chair of the Quality & Clinical Governance Committee			
Purpose (this paper if for)	Decision		Discussion		Assurance	
					X	
Has the report (or variation of it) been presented to another Committee / Meeting? If yes, state the Committee / Meeting: No.						
Executive Summary The Quality and Clinical Governance Committee has been established to provide oversight on any quality or equality impact relating to all commissioned services through its review and monitoring of quality surveillance metrics that may indicate an adverse impact on quality or safety and therefore require further mitigation to be considered. The Committee provides assurance to the Governing Body that any risk to equality and quality has been appropriately mitigated and how continuous improvement will be monitored. The Committee also monitors safeguarding and oversees the development of and approve policies relating to HR and Corporate. The following assurance report details key topics discussed at recent meetings.						
Recommendations The Governing Body is asked to receive the report as assurance.						
Monitoring An assurance report on key topics discussed at the Quality and Clinical Governance Committee will be brought to each Governing Body meeting.						
Any statutory / regulatory / legal / NHS Constitution implications			The Quality and Clinical Governance Committee is accountable to the Governing Body and is required to provide key messages from its meetings.			
Management of Conflicts of Interest			No conflicts of interest have been identified prior to the meeting.			
Communication / Public & Patient Engagement			Key Messages are published with the Governing Body Papers.			
Financial / resource implications			None identified.			
Significant Risks to Consider			No significant risks to consider.			
Outcome of Impact Assessments completed			Not applicable.			

Kate Kennady, Lay Member for Patient and Public Engagement and Chair of the Quality and Clinical Governance Committee

Quality and Clinical Governance Committee

Key Messages

The Committee met virtually on 4 February 2021 using Microsoft Teams. The committee was quorate, and there were no declarations of interest in relation to the business of the meeting.

Items Approved:

- The Minutes from the 3 December 2020 were approved as a true and accurate record of the meeting.
- Giant Cell Arteritis – the updated referral support service guidance for giant cell arteritis/temporal arteritis was APPROVED for the Scarborough and Ryedale locality only. The QCGC supports indirect publishing with a link to the NHS Vale of York CCG; the QCGC also supports the use of the non-North Yorkshire guidance.
- Equality and Diversity Plan Objectives – the QCGC was ASSURED that the CCG fulfils its statutory duties and responsibilities as detailed within the plan and RECOMMENDS the plan be forwarded to the next meeting of the Governing Body. A suggestion was made to promote the safeguarding of vulnerable people and this would be incorporated into the plan.
- Quality/Equality Impact Assessments
 - Varicose Veins
 - Gamete Harvesting and Preservation
 - Access to Infertility Services
 - Health Optimisation
 - Cholecystectomy
 - Flash Glucose Monitoring
 - Rhinoplasty
 - Acne
 - Blepharoplasty
 - Exogen Therapy
- The QCGC ACCEPTED the equality/quality impact assessments as listed above and RECOMMENDED them for discussion at the next meeting of the Governing Body.
-
- Safeguarding Adults Annual Report – APPROVED.

All other agenda items were noted as listed below:

- Care Home Oximetry@home Protocol
- Forward Plan
- CHC Choice Policy
- QCGC Annual Report
- QCGC Complaints Annual Report
- QCGC Annual Committee Effectiveness Review
- Receipt of Internal Audit Reports
- Significant Risk Review - nil report.
- Sustainability Action Plan.
- COVID-19 Update
- Quality, Patient Safety and Performance Update by Exception
- Adult CHC Report and EOL/Fast Track
- LeDER Report
- Children's Services and Children's Continuing Healthcare Report
- Medicines Management – Drug Monitoring and Board Notes
- Safeguarding Children's Annual Report
- Medicines Management Annual Report